Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Switching ART in a Heavily Treatment–Experienced Patient With HIV
  • CME

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: March 24, 2021 Expiration: March 23, 2022
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
ViiV Healthcare
Roger Bedimo, MD, MS, FACP
David A. Wohl, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Develop individualized treatment plans for patients who are heavily treatment experienced and may benefit from regimen simplification or optimization

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Roger Bedimo, MD, MS, FACP

Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas

Roger Bedimo MD, MS, FACP, has disclosed that he has received funds for research support from ViiV and consulting fees from Merck, Theratechnologies and ViiV.
David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader,  AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director, HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

David A. Wohl, MD, has disclosed that he has received funds for research support from Gilead Sciences, Merck, and ViiV and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV.

Staff

Tiffany Hensley-McBain, PhD

Scientific Director

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Jennifer Swanson, PharmD

Editorial Contributor

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with heavily treatment–experienced HIV.

Goal

The goal of this activity is to improve healthcare professionals’ competence in assessing and managing complex HIV cases and individuals who are heavily treatment experienced.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-068-H02-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 24, 2021, through March 23, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Switching ART in a Heavily Treatment–Experienced Patient With HIV
  • CME

Loading...
In this call between colleagues, expert faculty discuss how they approach ART optimization in a virologically suppressed patient with HIV and multiclass resistance, including a discussion of relevant guidelines and data.
Roger Bedimo, MD, MS, FACP
David A. Wohl, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: March 24, 2021 Expiration: March 23, 2022

Related Content

Drs Monica Gandhi and Joseph Eron discuss next-line ART options for a heavily treatment-experienced patient with multiclass resistance .

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 19, 2021 Expired: April 18, 2022

Clinical Care Options (CCO) commentary by Dr Zhao Yan on data presented at CROI 2021 on the impact of the COVID-19 pandemic on HIV treatment

Dr. Zhao Yan Released: April 19, 2021

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Clinical Care Options (CCO) commentary by Nelly Mugo, MD, on new data from Kenya on STI incidence and on PrEP uptake from CROI 2021

Nelly Mugo, MBChB, MMed, MPH Released: April 15, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue